Although a recent review [38] concluded that pemigatinib did not demonstrate efficacy in glioblastoma based on available clinical trials, it is important to note that this study primarily evaluated monotherapy, often in patients with previously treated recurrent GBM or other primary CNS tumors harboring FGFR1–3 mutations or fusions/rearrangements. This evidence concerns the gene FGFR1 and glioblastoma.